Estrella Immunopharma (NASDAQ:ESLA) Shares Up 1.3% – Here’s What Happened

Estrella Immunopharma, Inc. (NASDAQ:ESLA) rose 1.3% during mid-day trading on Thursday . The stock traded as high as $1.6350 and last traded at $1.58. Approximately 272,307 shares traded hands during trading, an increase of 87% from the average daily volume of 145,470 shares. The stock had previously closed at $1.56.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ESLA. D. Boral Capital reissued a “buy” rating and issued a $16.00 price objective on shares of Estrella Immunopharma in a research note on Monday, November 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Estrella Immunopharma in a research report on Friday, October 31st. Finally, Wall Street Zen upgraded shares of Estrella Immunopharma to a “hold” rating in a research note on Saturday, November 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Estrella Immunopharma has an average rating of “Hold” and an average target price of $16.00.

Estrella Immunopharma Price Performance

The business’s 50 day moving average is $2.03 and its two-hundred day moving average is $1.35. The firm has a market capitalization of $59.68 million, a PE ratio of -4.65 and a beta of 0.53.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.